28 reports of this reaction
2.1% of all SELEGILINE HYDROCHLORIDE reports
#8 most reported adverse reaction
HALLUCINATION, VISUAL is the #8 most commonly reported adverse reaction for SELEGILINE HYDROCHLORIDE, manufactured by Bausch Health US, LLC. There are 28 FDA adverse event reports linking SELEGILINE HYDROCHLORIDE to HALLUCINATION, VISUAL. This represents approximately 2.1% of all 1,332 adverse event reports for this drug.
Patients taking SELEGILINE HYDROCHLORIDE who experience hallucination, visual should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HALLUCINATION, VISUAL is a less commonly reported adverse event for SELEGILINE HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to hallucination, visual, the following adverse reactions have been reported for SELEGILINE HYDROCHLORIDE:
The following drugs have also been linked to hallucination, visual in FDA adverse event reports:
HALLUCINATION, VISUAL has been reported as an adverse event in 28 FDA reports for SELEGILINE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
HALLUCINATION, VISUAL accounts for approximately 2.1% of all adverse event reports for SELEGILINE HYDROCHLORIDE, making it a notable side effect.
If you experience hallucination, visual while taking SELEGILINE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.